curacle co.,ltd. (365270.KQ) Stock

365270.KQ logo

curacle co.,ltd.

365270.KQSouth Korea
Healthcare

Company profile

curacle reported revenue of 7.10 million KRW for fiscal year 2025, and a net loss of 18.11 billion KRW. That is a net profit margin of -255057.9% for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 1.05 billion KRW. In Q1 2026 it reported a net loss of 3.14 billion KRW, against a net loss of 4.12 billion KRW a year earlier. Our analysis of its filings shows revenue shrinking from 10.29 billion KRW in fiscal year 2023 to 7.10 million KRW in fiscal year 2025, 97.4% a year on average.

What stands out

  • Revenue fell 99.6% in fiscal year 2025, from 1.63 billion KRW in fiscal year 2024, after a fall of 84.1% the year before.
  • It reported a net loss in each of its last 5 fiscal years (2021 to 2025).
  • Its net profit margin over the last four reported quarters was -92.1%, against a median of 0.9% for 6 listed companies of similar size in its industry.

Figures from company filings; latest fiscal year ended December 31, 2025.

About curacle co.,ltd.

curacle co.,ltd., a bio-venture business, engages in the research and development of drugs for intractable vascular and metabolic diseases due to aging. The company's products in pipeline include CU06, a next-generation oral therapy, which completed phase 2a clinical trial for the treatment of diabetic macular edema; CU01, which completed Phase 2b clinical trial for Nrf2 activation and inhibition of TGF- ß/Smad signaling; MT-101, a fully humanized Tie2 agonist antibody for the treatment of renal diseases; and MT-103, a bispecific antibody combining Tie2 agonist and anti-VEGF functions for the treatment of wAMD. It also develops MT-105 for the treatment of irritable bowel diseases; MT-201, a non-bleeding anti-thrombotic antibody targeting PD-X; MT-202, a dual-mechanism therapy combining PD-X inhibition and Tie2 agonism for the treatment of acute ischemic stroke and heart failure with preserved ejection fraction; CU71, a next-generation neurovascular stabilizer for the treatment of alzheimer's disease; and CP01-R01, a first oral endothelial stabilizer–based candidate for companion animal CKD therapy. In addition, the company develops SOLVADYS, proprietary oral small-molecule platform for the treatment of endothelial dysfunction; and EAGLES, a flagship platform of Maptics for next-generation biologics. curacle co.,ltd. was incorporated in 2016 and is headquartered in Seoul, South Korea.

Largest shareholders

  • Yeong-Geun Kwon8.17 %8.17%
  • Young-Myung Kim0.2888 %0.29%
  • Yong Hwang0.1264 %0.13%
  • Yeon-Sung Choo0.0451 %0.05%
  • Jung-In Pyo0.0451 %0.05%

Share of the company, as of September 25, 2026

Leadership

  • Jaehyeon Yoo — Chief Executive Officer
  • Young-geun Kwon — Founder & Chairman

How much revenue does curacle make?

curacle reported 7.10 million KRW in revenue for fiscal year 2025, down 99.6% from 1.63 billion KRW in fiscal year 2024. In Q1 2026 revenue was 1.05 billion KRW.

What companies are similar to curacle?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Hyundai Pharmaceutical Co., Ltd. (004310.KS), Huons Co., Ltd. (243070.KQ), Reyon Pharmaceutical Co., Ltd. (102460.KS), DAE HWA Pharmaceutical Co., Ltd. (067080.KQ).

How has curacle's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 6.25 billion KRW; FY2022, 3.58 billion KRW; FY2023, 10.29 billion KRW; FY2024, 1.63 billion KRW; FY2025, 7.10 million KRW.

Has curacle made a profit in recent years?

Net income by fiscal year: FY2021, a loss of 6.68 billion KRW; FY2022, a loss of 11.41 billion KRW; FY2023, a loss of 11.59 billion KRW; FY2024, a loss of 14.89 billion KRW; FY2025, a loss of 18.11 billion KRW. It reported a net loss in each of these 5 years.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
HeadquartersSeoul, South Korea
ExchangeKOSDAQ
TimezoneAsia/Seoul (KST)

Contact & Links

Address
23-1, Hyoryeong-ro, Seoul, 06694
Phone
82 2 3487 0077
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “curacle co.,ltd. (365270.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/365270.KQ

LinkedInLinkedInXXYouTubeYouTube